Graft infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Graft infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Virus-Specific T-Cells for Treating Resistant Viral Infections in Young Patients After Stem Cell Transplant https://clinicaltrials.eu/trial/study-on-virus-specific-t-cells-for-treating-resistant-viral-infections-in-young-patients-after-stem-cell-transplant/ Wed, 29 Apr 2026 15:02:45 +0000 https://clinicaltrials.eu/trial/study-on-virus-specific-t-cells-for-treating-resistant-viral-infections-in-young-patients-after-stem-cell-transplant/ This clinical trial is focused on helping patients who have undergone an allogeneic hematopoietic stem cell transplant and are experiencing viral infections that do not respond to regular drug treatments. The viruses being studied include Cytomegalovirus (CMV), Adenovirus, Epstein-Barr virus (EBV), and BK virus. These infections can be particularly challenging for young patients, aged 0 to 30 years, who have received a stem cell transplant.

The treatment being tested in this study involves a special type of cell therapy using virus-specific T-cells, which are a kind of immune cell. These T-cells are selected from a family donor and are designed to target and fight the specific viruses causing the infections. The treatment is given as a solution through an intravenous infusion, which means it is delivered directly into the bloodstream.

The main goal of the study is to evaluate the safety of this cell therapy. Participants will receive the treatment and be monitored for any changes in their health, including any side effects or improvements in their condition. The study will also look at how well the treatment works in reducing the viral infections and improving the overall health of the participants. The trial is expected to continue until July 2025.

]]>